[go: up one dir, main page]

WO2007057924A1 - Composition laxative a base de triphala - Google Patents

Composition laxative a base de triphala Download PDF

Info

Publication number
WO2007057924A1
WO2007057924A1 PCT/IN2006/000462 IN2006000462W WO2007057924A1 WO 2007057924 A1 WO2007057924 A1 WO 2007057924A1 IN 2006000462 W IN2006000462 W IN 2006000462W WO 2007057924 A1 WO2007057924 A1 WO 2007057924A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition according
constipation
bowel
triphala
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2006/000462
Other languages
English (en)
Inventor
Rajesh Jain
Kour Chand Jindal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Panacea Biotec Ltd
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Publication of WO2007057924A1 publication Critical patent/WO2007057924A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/68—Plantaginaceae (Plantain Family)

Definitions

  • the present invention relates Io novel compositions comprising at least one bowel evacuant and a saccharide component optionally with at least one component selected from a group comprising antacid, antiflat ⁇ lant, prokinetic, antispasmodic, anticholinergic, stool softener, anti-nauseating/anti-emetic agent, ton i Tier and the like or their mixtures, and optionally with one or more excipient(s); the process of preparation and method of using such compositions.
  • the compositions of the present invention are useful as a pharmaceutical or a dietary supplement.
  • the compositions of the present invention are highly effective in the overall management of constipation including the prophylaxis and/or amelioration and/or treatment of not only the constipation but also associated disorders thus providing a better relief to the user.
  • Constipation is a condition in which a person has uncomfortable or infrequent bowel movements. Generally, a person is considered to be constipated when bowel movements result in passage of smal l amounts of hard, dry stool, usually fewer than three times a week. People who are constipated may find it difficult and painful to have a bowel movement. Other symptoms of constipation include feeling bloated, uncomfortable, and sluggish. The hard and dry stools of constipation occur when the colon absorbs too much water or if the colon's muscle contractions arc slow or sluggish, causing the stool to move through the colon too slowly.
  • constipation can lead to complications such as hemorrhoids caused by straining to have a bowel movement or anal fissures caused when hard stool stretches the sphincter muscle or rectal prolapse caused by straining which leads to a small amount of intestinal lining to push out from the anal opening. Constipation may also cause hard stool to pack the intestine and rectum so tightly that normal pushing action of colon is not enough to expel stool. This condition, called fecal impaction, occurs mostly in children and older adults.
  • US patent no. 5,320,847 relates to a method of agglomerating, and thereby increasing the dispensability and mixability of, a powdered psyllium hydrop) ⁇ ilic miicilloid combinate utilizing acacia dissolved in water as the agglomerating agent.
  • US patent no. 5,651 ,988 claims a combination osmotic and bulk-forming laxative comprising lactitol and psyllium hydrophilic miicilloid powder.
  • US patent no. 4,32 1 ,263 describes a
  • US publication no. 200501529S9 claims a method for treating irritable bowel syndrome (IBS), using an osmotic laxative and a fiber which specifically provides relief from I BS by simultaneously ameliorating both constipation and diarrhea.
  • IBS irritable bowel syndrome
  • fibers are psyllium, partial ly-hydnolyzed guar gum and cellulose.
  • PCT publication no. 0 WO2005051361 relates to solid dosage form colonic purgative formulations particularly comprising at least one soluble binder and at least one purgative and methods of their use.
  • PCT publication bearing no. WO20040781 82 relates to a novel composition which 5 combines defined proportions of a soluble saccharide which is poorly absorbed by the organism (the most widely known being disaccharides such as lactulose, lactitol, trehalose) and an antiflatulent from the siloxane group (the most widely known being polydimethylsiloxanes such as simethicone, dimethicone).
  • 0334407 relates to a method of preparing a solid composition of lactulose in a simple way.
  • the lactulose syrup is mixed with Fiberforni f M i.e. a fiber product based on 5 the husks of corn grains having a fiber content of more than 80%. The mixture is spread, dried, crushed and optionally sieved.
  • US patent no. 5,81 7,330 describes jellied and translucent emulsion, characterized in that it consists essentially of about 75 (o 85 parts by weight of liquid paraffin oil and 25 to 15 parts by weight of a sweetened aqueous solution of lactulose containing a total of 54 to 66% by weight dry matter.
  • Laxatives are among the most commonly used drugs or additives for treatment of constipation. Most are quite safe when used judiciously, intermittently when possible, and in the absence of contraindications. Bulking agents and nonabsorbable compounds such as lactulose can cause bloating. Osmotic laxatives containing poorly absorbable
  • ions such as magnesium or phosphate can cause metabolic disturbances, particularly in the presence of renal impairment.
  • Polyethylene glycol solutions are emerging as an effective and safe mode of treatment for chronic constipation. Purgatives are drastic laxatives causing a cleansing or watery evacuation of the bowels, usually with a griping pain. 0
  • Triphala is an ayurvedic herbal formula composed of three fruits namely Harada (Hantaki), AmIa (Ainalaki) and Behada ⁇ Bibhitaki), and is an effective laxative which also supports the body's strength.
  • the major components of Triphala are condensed tannins, catechins, along with gallic and ellagic acid which are the building blocks of 5 the tannins. Because of its high nutritional value, Triphala uniquely cleanses and detoxifies at the deepest organic levels without depleting the body's reserves.
  • Triphala corrects constipation, cleanses and tonify the gastrointestinal tract; detoxifies the whole body and improves digestion and assimilation; reduces high blood pressure and hypertension and improves blood circulation; acts as anti-viral, anti-bacterial, powerful 0 anti-oxidant; and has anticancer and anti-allergy properties.
  • Triphala is also helpful in liver disorders, acts as an expectorant and corrects diverticulitis. It is very effective in Irritable Bowel Syndrome (IBS) and Ulcerative Colitis.
  • IBS Irritable Bowel Syndrome
  • Ulcerative Colitis Triphala is a powerful eye rejuve ⁇ ator for treatment of conjunctivitis, progressive myopia, the early stages of glaucoma and cataracts.
  • H is highly anti-inflammatory, anti-viral and also stimulates bile-flow and peristalsis.
  • Triphala is mild, non-habit forming, and a rejuvenative.
  • Triphala (trifala) is so effective because its three herbs are potent healers.
  • the herb Amalalci Emblica officinalis or PhyUanth ⁇ s emblica
  • the herb Haritaki (Terminal ia chebitla) the Vietnamese "king of medicine” is a classic heart-brain-longevity tonic and balances " VcUo '.
  • the herb Bibhitaki (Terminalia be/erica) is a powerful rejuvenative that reduces liver and heart disease; improves the voice, vision and promotes the growth of hair and
  • triphala helps to feel pure, light and revitalized; removes toxins, accumulations, gas and distention; nourishes the nervous system, blood and muscle; increases digestion, assimilation and reduces fat; detoxifies almost every system in the body and regulates the metabolism.
  • triphala extract possess the ability to scavenge free radicals such as DPPH and superoxide primarily
  • Ajwain oil is an essential oil obtained from the dried fruits of Trachysperimmi amwi.
  • the essential oil (2.5 to 5% in the dried fruits) is dominated by thymol (35 to 60%); 5 furthermore, ⁇ -pinene, p-cymene, limonene and ⁇ -terpinene have been found.
  • the oil of ajwain is an almost colorless to brownish liquid with characteristic odour and a sharp hot taste.
  • Ajwain oil is highly effective as a remedy for gastrointestinal disorders such as for relieving flatulence, dyspepsia, colic, diarrhea, spasmodic disorders and indigestion. 0
  • Fibers are often used for the treatment of constipation.
  • a fiber is the non-digested part of plant food and adds bulk to the stools by absorbing water.
  • There are two types of Fiber namely soluble and insoluble. Soluble fiber dissolves in water and is found in oat bran, barley, peas, beans, and citrus fruits. Insoluble fibers arc found in wheat bran and some vegetables. Fiber increases the transit time of the colon and decrease the pressures within the colon. Fibers such as Psyllium have been reported to inhibit lactulose- induced colonic mass movements and to benefit patients with irritable bowel syndrome, 5 improving both constipation and diarrhea (Washinton N et al. The American journal of clinical nutrition, 1998, 67(2), 3 1 7-321 ).
  • Psyllium is the common name used for several members of the plant genus Plantago whose seeds are used commercially for the production of mucilage.
  • the genus Plantago contains over 200 species.
  • P ovula and P psyllium are produced commercially in several European countries, the former Soviet
  • Senna is the common name for many species in the genus Cassia, both in the subfamily Caesalpinioideae. The term '"Senna' " is often used specifically for
  • Senna contains hydro ⁇ yanthracene glycosides known as sennosides. These glycosides stimulate colon activity and thus have a laxative effect. Also, these glycosides increase fluid secretion from the colon, with the effect of softening the stool and increasing its bulk (Leng-Peschlow E. Dual; effect of orally administered sennosides on large intestinal transit and fluid absorption in the rat. 0 J P harm Pharmacol 1986; 38:606-10).
  • Double-blind trials have confirmed the benefit of senna in treating constipation (Passmore AP, Davies KW, Flanagan PG, ct al; A comparison of Agiolax and Lactulose in elderly patients with chronic constipation. Pharmacol I 993;47(suppl l ):249-52 & Kinnunen O, Winblad 1, Koistincn P, Salokannel J; Safety and efficacy of a bulk laxative containing senna versus lactulose in 5 the treatment of chronic constipation in geriatric patients. Pharmacol 1993; 47(suppl l ):253-5).
  • Constipation induced by drugs such as the anti-diarrheal medicine loperamide (Imodium®) has also been shown to be improved by senna in a clinical trial (Ewe K, Ueberschaer B, Press AG; Influence of senna, fibre, and fibre & senna on colonic transit in loperamide-induced constipation. Pharmacol 1993; 47(st ⁇ ppl 1 ):242- 0 8).
  • Constipation is often associated with several disorders such as gas, bloating, cramps, acidity, nausea, irritation, abdominal discomfort and pain.
  • compositions which would be effective in the overall management of constipation including the prophylaxis or amelioration or treatment of not only the constipation but also associated disorders thus providing a better relief to the user.
  • novel compositions of the present invention overcomes such limitations of prior art.
  • compositions comprising at least one bowel evacuant as the active agent and a saccharide component, optionally with at least one component selected from a group comprising antacid, stool softener, antiflatulant, prokinetic, anti-emetic and tonifier, and optionally one or more excipient(s).
  • compositions comprising at least one laxative and/or a purgative as the bowel evacuant and a saccharide component, optionally with at least one component selected from a group comprising antacid, stool softener, antiflatulant, prokinetic, anti-emetic and tonifier, and optionally one or more excipient(s).
  • compositions comprising at least one laxative and/or a purgative as the bowel evacuant, a saccharide component and at least one tonifier, optionally with at least one component selected from a group comprising antacid, stool softener, antiflatulant, prokinetic and anti-emetic, and optionally one or more excipient(s).
  • compositions comprising ispaghula as the bowel evacuant and lactulose as the saccharide component, triphala as the tonifier, optionally with at least one component selected from a group comprising docusate sodium as the stool softener, simethicone as the antiflatulant, antacid and prokinetic, and one or more excipients.
  • It is an objective of the present invention to provide novel compositions comprising ispaghula and triphala as bowel eva ⁇ iants and lactulose as the saccharide component, optionally with at least one component selected from a group comprising docusate sodium as the stool softener, simethicone as the antiflatulant, antacid and prokinetic, and one or more excipients.
  • compositions comprising t ⁇ ' phala as the as the bowel evacuant and lactulose as the saccharide component, optionally with at least one component selected from a group comprising peppermint, fennel, ajwain, mentlia extract and lactobacillus optionally with at least one antacid and/or an antiflatulant and/or a prokinetic, and one or more excipients,
  • novel compositions of the present invention can be manufactured for pharmaceutical use or can be used as a dietary supplement and are useful in the overall management of constipation including the prophylaxis and/or amelioration and/or treatment particularly of constipation and associated disorders.
  • the present invention provides novel composition comprising at least one bowel evacuant as the active agent and a saccharide component, optionally with at least one component selected from a group comprising antacid, stool softener, antiflatulant, prokinetic, anti-emetic and tonifier, and optionally one or more excipient(s).
  • novel compositions comprising at least one laxative and/or a purgative as the bowel evacuant and a saccharide component, optionally with at least one component selected from a group comprising antacid, stool softener, antiflatulant and prokinetic agent, and one or more excipients.
  • novel compositions comprising at least one laxative and/or a purgative as the bowel evacuant, a saccharide component and at least one tonifier, optionally with at least one component selected from a group comprising antacid, stool softener, antiflatulant and prokinetic, and one or more excipients.
  • the bowel evacuant is a laxative such as triphala or ispaghula or a purgative such as senna;
  • the saccharide component is lactulose, the stool softener is docusate sodium, the antiflatulant is simethicone;
  • the prokinetic/anti-nauseating/anti-emetic agent is domperidone or tegaserod.
  • a novel composition comprising ispaghula as the bowel evacuant, lactulose as the saccharide component, triphala as the tonifier and optionally with at least one component selected from a group comprising docusate sodium as the stool softener and/or simethicone as the anliflatulant optionally with at least one antacid and/or a prokinetic, and one or more excipients.
  • a novel composition comprising ispaghula and triphala as bowel evacuants and lactulose as the saccharide component. optionally docusate sodium as the stool softener and/or simethicone as the antiflatulant optional ly with at least one antacid and/or a prokinetic, and one or more excipients.
  • the composition of the present invention comprises ispaghula as the bowel evacuant, lactulose as the saccharide component, and triphala as the tonifier, optionally with one or more excipients.
  • the composition of the present invention comprises triphala as the as the bowel evacuant and lactulose as the saccharide component, optional ly with at least one component selected from a group comprising peppermint, fennel, ajwain, inentha extract and lactobacillus optionally with at least one antacid and/or an antiflatulant and/or a prokinetic, and one or more excipients.
  • the bowel evacuant is selected from but not limited to a group comprising triphala; bulk laxatives such as ispaghula powder, methylcellulose (Citrucel), polycarbophil, malt soup extract, ethulose, sterculia, linseed, triticum or mixtures thereof; osmotic laxatives such as magnesium carbonate, magnesium oxide, magnesium peroxide, magnesium sulfate, mineral salts in combination, sodium sulfate, pentaerithrityl, macrogol, glycerol, sodium phosphate, magnesium citrate, sodium tartrate, or mixtures thereof; stool softeners such as docusate, poloxamer 188, dioctyl sodium sulfosuccinate, or mixtures thereof; lubricant/emollient such as mineral oil; hydrating agents such as dibasic sodium phosphate, magnesium citrate, magnesium hydroxide (Milk of Magnesia),
  • the bowel evacuant of the present invention is lspaghula or Triphala either used as an extract or in the powder form.
  • the extract can be aqueous or non-aqueous.
  • the solvents used in the non-aqueous extraction process is selected from but not limited to a group comprising alcohols such as methanol, ethanol, butanoL isopropyl alcohol or the like; acetone; glycerol; ethylacetate and alkylene glycols such as methylene glycol, ethylene glycol, propylene glycol or the like used either alone or in combination thereof.
  • a hydro-alcoholic extract is prefered.
  • Triphala extract The general procedure for the preparation of the Triphala extract is as follows: Equal parts of dried Amalaki (Emblica officinalis or Phy/lanlhiis embhea), Haritaki ( Terminalia chebula) and Bibhitaki ⁇ Terminalia be/erica) arc taken and mixed together followed by pulverization.
  • the powder thus obtained (hereinafter referred to as 'Triphala powder " ) is then extracted with a suitable solvent (aqueous, non-aqueous or hydro-alcoholic) preferably by applying heat.
  • a suitable solvent aqueous, non-aqueous or hydro-alcoholic
  • the extraction is preferably done 3-5 times under heat and reflux conditions to ensure proper extraction.
  • the solvent is removed from the liquid extract to obtain the dry extract.
  • the dry extract (referred to hereinafter as 'Triphala extract') thus obtained is preferably sifted through a suitable sieve to break any lumps or agglomerates.
  • the general procedure for the preparation of the psyllium seed husks extract is as follows: Milled psyllium seed husks were stirred with potassium hydroxide containing sodium borohydride in a nitrogen atmosphere. The mixture was cent ⁇ ' fuged. The supernatant was decanted from an insoluble fraction that had settled out in the centrifuge bottle. The insoluble fraction was stirred with fresh potassium hydroxide-sodium borohydride solution and re-centrifuged. The supernatants from both centrifugations were combined.
  • the pH of the combined supernatants was adjusted to 4.5 with glacial acetic acid, with stirring, at ambient temperature, then again centrifuged.
  • the supernatant was decanted from a gel mass that had settled out in the 5 centrifuge bottle.
  • the gel was washed gently with water to remove adhering supernatant solution and this wash water was added to the supernatant.
  • the gel fraction was desiccated by treatment with 95% ethanol and finally washed with diethyl ether and dried. Prior to desiccating, in some instances the fraction was further purified by repeating the alkaline solubilization and acidification steps described above.
  • the gel I O was re-suspended in potassium hydroxide, acidified to pH 4.5 and centrifuged to recover the gel.
  • the tonifier used in the composition is triphala.
  • the bowel evacuant comprises 5 a mixture of Triphala and lspaghula.
  • the Triphala particularly acts as a tonifier and deloxifier especially for the gastro-intestinal tract (GIT).
  • GIT gastro-intestinal tract
  • the saccharide component is selected from but not limited to a group comprising lactulose, lactitol, sorbitol, mannitol, maltodextrin, dextran. sucrose, maltitol, dextrose and the like or mixtures thereof. 5
  • the purgatives useful in the present invention include but not limited to a group comprising casanthranol, cascara, aloe, castor oil, dehydrocholate, phenolphthalein, senna, sennosides, sodium picosulfate, dantron, bisoxatin or the like used either alone or in combination thereof.
  • the dried ripe fruits, pods or leaves of Senna preferably 0 Cassia angustifolia
  • Senna preferably 0 Cassia angustifolia
  • Particularly preferred bulk laxatives for use in the present invention are fibers.
  • Two types of fibers namely soluble and insoluble can be used in the composition of the present invention.
  • Soluble fibers are viscous, gel-forming fibers which absorb water and makes stools softer and easier to pass.
  • soluble fibers are the edible parts of plants or similar carbohydrates resistant to digestion and absorption in the human small intestine with complete or partial fermentation in the large intestine. Fermentation of the undigested soluble fibers occurs by the action of colonic bacteria, producing gases and short-chain fatty acids such as butyric, acetic, propionic, and valeric acids.
  • Soluble fibers found in psyllium seed husk (about 66% soluble fibers); vegetable gums from legumes (guar gum, locust bean gum) and gummy exudates (gum acacia and tragacanth); seed mucilages from oats, rye and barley; mucilages from certain vegetables and roots such as broccoli, carrots, lady fingers, yam; pectin from fruits and vegetables are particularly used.
  • Insoluble fibers are indigestible cellulosed and lig ⁇ ified vegetable fibers found in cereal brans and fruit skins, which absorb water but do not dissolve in it. The insoluble fibers are also not fermented in the intestine.
  • Insoluble fibers useful in the present invention are found in fruits, vegetables, whole grain breads, and cereals. Wheat bran contains mostly insoluble fiber, while oat bran contains about 7% soluble fiber. Synthetic fibers may also be useful in the present invention. Several synthetic water soluble or water absorbing fibers have been prepared by modification of cellulose and other natural fibers such as methyl cellulose, carbo ⁇ ymelhyl cellulose, polycarbophil and the like.
  • the novel composition of the present invention can be manufactured for pharmaceutical use or can be used as a dietary supplement.
  • the composition of the present invention particularly upon daily use help in restoring normal bowel functions, and also tonifies and detoxifies the GlT.
  • a blend of Lactobacillus cultures and/or other useful microorganisms with or without an amino acid such as L-lysine which colonize the intestine can also be used as an additional component.
  • These cultures continually produce enzymes which support the digestive system and normalize the intestine, which aids normal digestion. It also provides relief for cramps, bloating, diarrhea, constipation and urgency.
  • probiotics are preferably selected from but not limited to different Lactobacillus species used either alone or in combination such as Lactobacillus reiiieri and Lactobacillus paracasei.
  • Antacids useful in the present invention are selected from but not limited to a group comprising alkaline earth metal oxides, peroxides, hydroxides, and the like or mixtures 5 thereof.
  • a ⁇ ti-gas/antiflatulant agents useful in the present invention is selected from but not limited to a group comprising simethicone, dimethicone, bisacodyl, alpha- galactosidase enzyme, activated charcoal and the like or mixtures thereof. These agents particularly aid in the reduction of acid and gas/ flatulence and the accompanying lower abdominal pain.
  • Prokinetic agents useful in the compositions of the present invention primarily to improve the motility of the gastrointestinal tract are selected from but not limited to a group comprising 5HT4 agonist and 5HT3 antagonist such as cisapride, itopride, mosapride, domperidone. metoclopramide, tegaserod and the like or mixtures thereof.
  • Natural prokinetics such as Dai-kenchii-to can also be used.
  • Smooth muscle relaxants such as mebeverine, peppermint oil and ajwain oil that have direct relaxant properties on gut smooth muscle are also useful.
  • Antispasmodic agents such as dicyclomine and hyoscyamine are also useful.
  • Anticholinergic agents that can be used in the present compositions as additional components act by decreasing the abnormal sensitivity of 0 cholinergic (muscarinic M 2) receptors in gut smooth muscle leading to significant improvement in abdominal pain and rectal urgency.
  • Other categories of active agents suitable for the treatment of disorders associated with constipation can also be used in the composition of the present invention.
  • the stool softener useful in the compositions of the present invention is selected from but not limited to a group comprising docusate 5 sodium, soluble fibers and the like or mixtures thereof. Such agents are employed to keep stool soft for easy natural passage and avoid painful anorectal conditions.
  • ingredients such as carminatives, ginger, turmeric, chamomile, caraway, fennel, mentha extract, or any other natural or semi-synthetic or synthetic 0 ingredient useful for the management of constipation or associated disorders can be used in the present invention to relax and calm the stomach and promote healthy digestion, preferably incorporated into the composition as oils.
  • the novel compositions of the present invention also assist in relief and discomfort of gas, acid indigestion, sour stomach, upset stomach or cramps associated with constipation.
  • Various enzymes either
  • lactase that helps in digesting the lactose, or milk sugar, found in dairy products
  • alpha-galactosidase that helps in digesting the complex sugars found in beans and other legumes and in cruciferous vegetables
  • protease that helps to break down the peptide bonds in protein foods
  • amylase that helps to digest the starchy carbohydrates in foods and lipase which helps to digest the fats in food.
  • Sweeteners such as aspartame, acesulfame, saccharine, cyclamate, glycyrrhizin, steviosides, talin, dihydrochalcone compounds and mixtures thereof can also be used in the present invention, preferably in a quantity from about 0.001 % to about 3% by weight of the composition.
  • the one or more excipient(s) that can be used for preparation of such compositions are selected from but not limited to diluents, disintegrants, binders, fillers, bulking agents, anti-adherants, anti-oxidants, buffering agents, colorants, flavoring agents, coating agents, plasticizers, organic solvents, stabilizers, preservatives, lubricants, glida ⁇ ts, chelating agents, release modifiers and the like known to the art used either alone or in combination thereof.
  • the fillers used in the present invention is selected from but not limited to a group comprising lactose, mannitol, sorbitol, starch, microcrystalline cellulose, xylitol, fructose, sucrose, dextrose, dicalcium phosphate, calcium sulphate, maltodextrin; polyethylene glycol such as PEG 100, PEG 2000, and PEG 6000; polyvinylpyrrolidone; sodium chloride; sodium citrate; citric acid; water soluble celluloses such as low viscosity hydroxyethyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose and the like or mixtures thereof.
  • the disintegranls used in the present invention include but not limited to starch or its derivatives, prege latinized starch, croscarmellose sodium, sodium starch glycollatc, and the like used either alone or in combination thereof.
  • the lubricants used in the present invention include but not limited to talc, magnesium stearate, calcium slearate, stearic acid, hydrogenated vegetable oil and the like used either alone or in combination thereof.
  • the release modifiers used in the present invention is selected from but not limited to a group comprising methacrylic acid copolymers such as Eudragit®, cellulosic polymer such as alkyl celluloses or hydroxyalkyl celluloses, gums, hydrophilic polysaccharides such as alginates, chitosan, scleroglucan or semi-synthetic polysaccharides; lipid components such as hydrogenated vegetable oi ls, waxes, glyceryl behenate and the like, or mixtures thereof.
  • the compositions of the present invention arc in the form of immediate release or controlled release or a combination of immediate release and controlled release particularly intended for delivery of the active agent(s) for an extended time period.
  • the dosage form may be in the form of tablets, minitablets, 5 capsules, pellets, granules, patches, powders, sachets or liquids or other dosage forms suitable for preferably oral administration, or enemas or suppositories.
  • the composition of the present invention is in the form of granules ,or powder filled into sachets or capsules, or granules or powder compressed into tablets that may be optionally filled into capsules.
  • composition of the present invention is highly effective in the management of constipation including prophylaxis and/or amelioration and/or treatment of constipation and associated disorders such as gas, bloating, cramps, acidity, irritation, abdominal pain and discomfort thus providing a better relief to the
  • composition of the present invention is useful in the treatment and/or management of diseases or disorders of the bowel primarily associated with constipation, diarrhea or indigestion.
  • the present invention also provides process for preparation of such compositions.
  • the process for preparation comprises mixing the active agent(s) and saccharide component optionally with at least one component selected from a group comprising antacid, stool softener, antiflatulant, prokinetic, anti-emetic and tonifier, and one or more excipient(s) and formulating into a suitable dosage form.
  • composition of the present invention comprises administering to a subject in need thereof an effective amount of the composition.
  • the composition of the present invention is useful for prophylaxis and/or amelioration and/or treatment of constipation and associated disorders such as gas, bloating, cramps, 0 acidity, irritation, abdominal pain and discomfort.
  • the composition of the present invention is useful as a dietary supplement to normalize bowel functions and provide relief from particularly constipation and other associated disorders.
  • compositions of the present invention are also useful in the treatment and/or management of diseases or disorders of the bowel primarily associated with constipation, diarrhea or indigestion.
  • compositions of the present invention are also useful for the treatment/management of Irritable Bowel Syndrome (IBS) predominantly associated with constipation.
  • IBS Irritable Bowel Syndrome
  • Step (i) Triphala extract and Lactitol were sifted through # 30 mesh sieve and mixed, ii) Aj wain oi l was added to the material of step (i) and m ixed, iii) Sodium saccharin was d issolved in Puri fied water. iv) The material of step (i i) was granulated using the material of step (ii i) to obtain the granules which were then dried, v) The material of step (iv) was passed through #30 mesh sieve to yield the product.
  • step (i) Triphala extract, Alpha-galactosidase enzyme and a part of Maltitol were m ixed, ii) Remaining part of Maltitoi and Sodium saccharin were dissolved in Purified water. iii) The material of step (i) was granulated using the material of step (ii) to obtain I O the granules which were then dried. iv) The material of step (iii) was passed through #30 mesh sieve to yield the product.
  • Step (i) Ispaghiila powder, Triphala powder and a part of Dextrose were mixed, ii) Sodium saccharin was dissolved in Purified water. ii i) The material of step (i) was granulated using the material of step (ii) to obtain 5 the granules which were then dried. iv) The material of step (i i i) was passed through #30 mesh sieve to yield the desired granules which is then provided in a suitable package,
  • Example-6 S. No. Ingredient Quantity (per serving)
  • step (ii) Triphala extract and a part of Lactulose were m ixed, ii) Peppermint oil and Fennel oil were dissolved in ethanol. iii) Remaining pail of Lactulose and Glycirrhizin were dissolved in Puri fied water, iv) The material of step (ii) was added to material of step (ii i) with continuous stirring. I O v) The material of step (i) was granulated using the material of step (iv) to obtain granules which were then dried. vi) The material of step (iii) was passed through #30 mesh sieve to yield the product.
  • step (i) Triphala extract, Polycarboph il and Sorbitol were mixed, ii) Docusate sodium and Citric acid were dissolved in Purified water. iii) The material of step (i) was granulated using the material of step (ii ) to obtain the granules which were then dried, iv) The material of step (i i i) was passed through #30 mesh sieve and m ixed with
  • step (iv) Magnesium stearate sifted through #40 mesh sieve, v) The materia) of step (iv) were compressed into tablets.
  • Pr ocedure i) Shortening (fat) and Lactulose were tilled together very lightly until a fluffy consistency was obtained. ⁇ ) Liquid glucose was added to step (i) and mixed. iii) Flour, lspaghula husk and Triphala extract were sifted through a #30 mesh sieve and the fraction passing through the sieve was collected, iv) Cocoa powder, Baking powder. Milk powder, Vanilla essence and Almond essence were mixed with the material of steps (ii) & (iii). v) The mixture of step (iv) was made into smooth & soft dough, rolled into required thickness and cut into desired size and baked at optimum temperature to obtain biscuits.
  • step (i) lspaghula powder, Maltodextrin, Domperidone and Sodium cyclamate were mixed together and sieved, ii) The mixture of step (i) is kneaded with a mixture of Ethanol and Demineralized water, granulated and dried. iii) Sodium bicarbonate, Tartaric acid, and the Flavoring agent are sieved and mixed well, iv) The mixture obtained in step (ii) and (iii) are mixed together and compressed into effervescent tablets.
  • Step (i) Ispaghula husk and a part of Lactulose were mixed. ii) Remaining part of Lactulose and Sodium saccharin were dissolved in Puri fied water, iii) The material of step (i) was granulated using the material of step (ii) to obtain the granules which were then dried. iv) The material of step (iii) was passed through #30 mesh sieve to yield granules.
  • Proced luurree : i) Shortening (fat) and Lactulose are tilled together very lightly until a fluffy consistency is obtained. ii) Add Liquid glucose to step (i) & mix again. iii) Sift Flour and Husk through a sieve of mesh no.30. iv) Mix Cocoa powder, Baking powder, Milk powder. Vanilla essence and Almond essence, and mix with step (ii) & (iii). v) The mixture of step (iv) is made into smooth & soft dough, rolled into required thickness and cut into desired size and baked at optimum temperature.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention a trait à une composition laxative comportant de l'ispagulha, une élément constitutif à base de saccharide et éventuellement du triphala mélangé avec un ou des excipient(s) éventuellement. L'invention a également trait à un processus et un procédé pour l'utilisation de telles compositions. Les compositions selon l'invention sont utiles en tant que produits pharmaceutiques ou suppléments diététiques et sont extrêmement efficaces dans la prise en charge globale de la constipation et des troubles associés, procurant un soulagement accru à l'utilisateur.
PCT/IN2006/000462 2005-11-21 2006-11-20 Composition laxative a base de triphala Ceased WO2007057924A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN3100DE2005 2005-11-21
IN3100/DEL/2005 2005-11-21
IN3353DE2005 2005-12-13
IN3353/DEL/2005 2005-12-13

Publications (1)

Publication Number Publication Date
WO2007057924A1 true WO2007057924A1 (fr) 2007-05-24

Family

ID=38048332

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2006/000462 Ceased WO2007057924A1 (fr) 2005-11-21 2006-11-20 Composition laxative a base de triphala

Country Status (1)

Country Link
WO (1) WO2007057924A1 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8017168B2 (en) 2006-11-02 2011-09-13 The Coca-Cola Company High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith
AT12928U1 (de) * 2010-11-04 2013-02-15 Norgine Bv Formulierungen
JP2013079199A (ja) * 2011-09-30 2013-05-02 Zeria Pharmaceutical Co Ltd 便秘改善薬
WO2013059881A1 (fr) * 2011-10-27 2013-05-02 Borody Thomas J Purgatifs électrolytiques
WO2013095111A1 (fr) 2011-12-14 2013-06-27 Disphar International B.V. Formulation de siméthicone
KR20140018210A (ko) * 2010-12-13 2014-02-12 토마스 줄리어스 보로디 위 및 결장 조제물 및 이의 제조 및 사용 방법
DE102012024434A1 (de) * 2012-12-14 2014-06-18 Regalismons S.A. Verstärkung der entschäumenden Wirkung von Polysiloxanen, zugehöriger Zusammensetzungen und Lösungen
EP2865371A1 (fr) * 2013-10-22 2015-04-29 Disphar International B.V. Granules à dissolution rapide
US9101160B2 (en) 2005-11-23 2015-08-11 The Coca-Cola Company Condiments with high-potency sweetener
US20150224127A1 (en) * 2009-10-14 2015-08-13 Gi Innovations, Pllc Colon cleansing of residual stool and secretions during colonoscopy
US9750778B2 (en) 2013-08-13 2017-09-05 Natreon, Inc. Terminalia chebula and Terminalia bellirica extracts for inhibition of xanthine oxidase
US10166219B2 (en) 2012-07-27 2019-01-01 Redhill Bipharma Ltd. Formulations and methods of manufacturing formulations for use in colonic evacuation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4459280A (en) * 1982-07-23 1984-07-10 G. D. Searle & Co. Psyllium hydrophilic mucilloid composition
WO1997006808A1 (fr) * 1995-08-18 1997-02-27 Xyrofin Oy Laxatifs a la fois osmotiques et augmentant le volume du bol fecal
US6187753B1 (en) * 1992-03-11 2001-02-13 The Procter & Gamble Company Psyllium drink mix compositions containing granulated base
EP1340431A1 (fr) * 2001-01-11 2003-09-03 The Sweet Life, Inc. Composition avec du Xylitol et une fibre alimentaire, utilisée dans des aliments et/ou des boissons
WO2007013093A2 (fr) * 2005-04-01 2007-02-01 Shiv Prakash Formulation laxative

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4459280A (en) * 1982-07-23 1984-07-10 G. D. Searle & Co. Psyllium hydrophilic mucilloid composition
US6187753B1 (en) * 1992-03-11 2001-02-13 The Procter & Gamble Company Psyllium drink mix compositions containing granulated base
WO1997006808A1 (fr) * 1995-08-18 1997-02-27 Xyrofin Oy Laxatifs a la fois osmotiques et augmentant le volume du bol fecal
EP1340431A1 (fr) * 2001-01-11 2003-09-03 The Sweet Life, Inc. Composition avec du Xylitol et une fibre alimentaire, utilisée dans des aliments et/ou des boissons
WO2007013093A2 (fr) * 2005-04-01 2007-02-01 Shiv Prakash Formulation laxative

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9101160B2 (en) 2005-11-23 2015-08-11 The Coca-Cola Company Condiments with high-potency sweetener
US8017168B2 (en) 2006-11-02 2011-09-13 The Coca-Cola Company High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith
US20150224127A1 (en) * 2009-10-14 2015-08-13 Gi Innovations, Pllc Colon cleansing of residual stool and secretions during colonoscopy
AT12928U1 (de) * 2010-11-04 2013-02-15 Norgine Bv Formulierungen
KR101947720B1 (ko) 2010-12-13 2019-02-14 샐릭스 파마슈티컬스 인코포레이티드 위 및 결장 조제물 및 이의 제조 및 사용 방법
US10092573B2 (en) 2010-12-13 2018-10-09 Salix Pharmaceuticals, Inc. Gastric and colonic formulations and methods for making and using them
KR20140018210A (ko) * 2010-12-13 2014-02-12 토마스 줄리어스 보로디 위 및 결장 조제물 및 이의 제조 및 사용 방법
JP2013079199A (ja) * 2011-09-30 2013-05-02 Zeria Pharmaceutical Co Ltd 便秘改善薬
RU2640920C2 (ru) * 2011-10-27 2018-01-12 Саликс Фармасьютикалз, ИНК. Электролитные слабительные средства
AU2012327212B2 (en) * 2011-10-27 2016-05-12 Rite-Prep Pty Ltd Electrolyte purgatives
JP2018008997A (ja) * 2011-10-27 2018-01-18 サリックス ファーマシューティカルズ，インコーポレイテッド 電解質下剤
WO2013059881A1 (fr) * 2011-10-27 2013-05-02 Borody Thomas J Purgatifs électrolytiques
WO2013095111A1 (fr) 2011-12-14 2013-06-27 Disphar International B.V. Formulation de siméthicone
US10166219B2 (en) 2012-07-27 2019-01-01 Redhill Bipharma Ltd. Formulations and methods of manufacturing formulations for use in colonic evacuation
DE102012024434A1 (de) * 2012-12-14 2014-06-18 Regalismons S.A. Verstärkung der entschäumenden Wirkung von Polysiloxanen, zugehöriger Zusammensetzungen und Lösungen
US10617761B2 (en) 2012-12-14 2020-04-14 Regalismons S.A. Compositions and solutions for colon cleansing
US9750778B2 (en) 2013-08-13 2017-09-05 Natreon, Inc. Terminalia chebula and Terminalia bellirica extracts for inhibition of xanthine oxidase
EP2865371A1 (fr) * 2013-10-22 2015-04-29 Disphar International B.V. Granules à dissolution rapide

Similar Documents

Publication Publication Date Title
CN112544920A (zh) 一种改善便秘的组合物及其制备方法
AU2016253140B2 (en) Plant extracts for the treatment of excess weight and obesity
WO2007057924A1 (fr) Composition laxative a base de triphala
Hoffmann Healthy digestion: A natural approach to relieving indigestion, gas, heartburn, constipation, colitis, and more
WO2005007179A1 (fr) Composition contenant du lotus moulu et/ou de l'extrait de lotus et une bacterie d'acide lactique
Sari et al. The potential of polysaccharides from various plants as constipation treatment
KR100549089B1 (ko) 장기능 및 변비 질환 개선용 건강 기능성식품
JP2005179316A (ja) 便秘改善作用を有する組成物
WO2008096171A2 (fr) Composition laxative naturelle destinée à traiter et prévenir la constipation par une action de nettoyage du côlon
KR102000170B1 (ko) 체지방 감소 및 장관면역활성 증진을 위한 건강보조식품
DE202008015430U1 (de) Zusammensetzung zur Behandlung von Verdauungsstörungen
CN1315411C (zh) 一种具有通便美容功能的保健品及制备方法
Mahboubi Prunus domestica as effective and acceptable treatment for stool softening and relief of constipation symptoms.
CN109090612A (zh) 一种润肠通便的中药食品及制备方法
JP2000041625A (ja) 食用組成物
RU2773084C2 (ru) Композиция для кратковременного и долговременного лечения запоров
EP3484494A1 (fr) Formulation pharmaceutique ou de complément alimentaire pour le traitement de la constipation
EP3706764B1 (fr) Composition destinée au traitement aigu et chronique de la constipation
KR20040024008A (ko) 변비 개선용 건강식품 조성물
WO2007013093A2 (fr) Formulation laxative
JP2004244389A (ja) 栄養補助食品
DE102014103832A1 (de) Zusammensetzung zur Behandlung von Magenbeschwerden
EP3687314B1 (fr) Composition pour le traitement de la constipation
KR100450055B1 (ko) 두과 식물을 주성분으로 함유하는 체질개선용 식품 조성물및 그로부터 제조되는 식품
CN108888723A (zh) 一种润肠通便的组合物及其制备方法与应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06821703

Country of ref document: EP

Kind code of ref document: A1